| 1311 |
Centers for Disease Control and Prevention |
Html |
en |
Mumps | CDC Features |
Mumps vaccine is the best way to protect your child against mumps, a contagious disease that can cause serious complications. |
| college | 0.233111 |
| health insurance | 0.380947 |
| best way | 0.430966 |
| insurance provider | 0.296669 |
| program | 0.233109 |
| children | 0.321615 |
| long-lasting problems | 0.305609 |
| highly vaccinated U.S. | 0.418681 |
| swollen jaw | 0.313968 |
| long-term health problems | 0.398518 |
| rubella | 0.25424 |
| diseases | 0.239648 |
| puffy cheeks | 0.319614 |
| effects | 0.237217 |
| viral encephalitis | 0.316183 |
| mumps vaccine | 0.821166 |
| rare cases | 0.298914 |
| high vaccination coverage | 0.392112 |
| mumps | 0.987273 |
| child | 0.39332 |
| doses | 0.250447 |
| mumps outbreaks | 0.701938 |
| vaccines | 0.313758 |
| fever | 0.238637 |
| cause | 0.224854 |
|
| sudden deafness | 0.314551 |
| immunization records | 0.323964 |
| MMRV vaccine | 0.420166 |
| trade school | 0.301263 |
| muscle aches | 0.315344 |
| combination vaccine | 0.517956 |
| healthcare professionals | 0.298044 |
| eligible children | 0.304683 |
| higher risk | 0.295749 |
| health insurance plans | 0.374364 |
| salivary glands | 0.319639 |
| mumps cases | 0.572791 |
| Talk | 0.241521 |
| varicella | 0.223804 |
| doctor | 0.253158 |
| rash | 0.223153 |
| MMR vaccine. Learn | 0.435683 |
| state VFC coordinator | 0.377972 |
| close-contact settings | 0.30226 |
| international travelers | 0.299874 |
| appetite | 0.222208 |
| measles | 0.252434 |
| MMR vaccine | 0.678751 |
| contagious disease | 0.421704 |
|
CLICK HERE |
| 8774 |
Centers for Disease Control and Prevention |
Html |
en |
Average Annual Rate of Eye-Related Emergency Department Visits for Injuries and Medical Conditions, by Age Group - United States, 2007-2010 |
Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: mmwrq@cdc.gov. |
| mmwrq@cdc.gov. | 0.497987 |
| reason | 0.43354 |
| eye-related ED visits | 0.930806 |
| endorsement | 0.437841 |
| injuries | 0.452377 |
| Alternate Text | 0.487387 |
| Human Services | 0.550093 |
| assistive technology | 0.503385 |
| MMWR HTML versions | 0.548961 |
| U.S. Department | 0.542656 |
| electronic PDF version | 0.545991 |
| e-mail | 0.435101 |
| eye injury | 0.576683 |
| period | 0.431836 |
| Contact GPO | 0.496259 |
| commercial sources | 0.485956 |
| current prices | 0.482146 |
| persons | 0.550177 |
| EDs | 0.441223 |
| medical conditions | 0.657622 |
| original paper copy | 0.548773 |
| United States | 0.490739 |
| age group | 0.671163 |
| original MMWR paper | 0.546328 |
|
| assistance | 0.417234 |
| title | 0.417105 |
| MMWR readers | 0.485529 |
| character translation | 0.482078 |
| result | 0.469668 |
| file | 0.417317 |
| eye-related visits | 0.790171 |
| Children | 0.431289 |
| eye-related visit rate | 0.869687 |
| format errors | 0.480793 |
| eye-related emergency department | 0.719876 |
| subject line | 0.501146 |
| Health | 0.426479 |
| Significant differences | 0.578174 |
| typeset documents | 0.484191 |
| trade names | 0.486012 |
| official text | 0.479602 |
| emergency departments | 0.574231 |
| average annual rate | 0.57245 |
| non-CDC sites | 0.483514 |
| information | 0.417327 |
| Accommodation | 0.417116 |
| eye-related medical condition | 0.861798 |
| electronic conversions | 0.479285 |
|
CLICK HERE |
| 10640 |
Centers for Disease Control and Prevention |
Html |
en |
Short and Extended Messages'Resources' Communicating in the First Hours |
The CERC training program educates people on the principles and application of crisis and emergency risk communication when responding to a public health emergency. |
| MPEG | 0.378858 |
| search | 0.263099 |
| PDF | 0.261307 |
| PPT | 0.446092 |
|
| DOC | 0.368812 |
| information | 0.262482 |
| different file formats | 0.938484 |
| page | 0.276773 |
|
CLICK HERE |
| 11297 |
Centers for Disease Control and Prevention |
Html |
en |
Ebola Virus Disease Information for Clinicians in U.S. Healthcare Settings |
null |
| clinical management | 0.512327 |
| Ebola Haemorrhagic Fever | 0.532569 |
| Direct Virus Involvement | 0.460055 |
| Stomatitis Virus-Vectored Ebola | 0.520509 |
| ebola virus | 0.921219 |
| Ann Intern Med. | 0.464851 |
| Mehta AK | 0.456496 |
| single-patient emergency IND | 0.456201 |
| post-exposure prophylaxis | 0.470396 |
| additional information | 0.455817 |
| Ebola Response Team | 0.52438 |
| Davey RT Jr | 0.481003 |
| Lancet Infect Dis. | 0.488632 |
| Engl J Med. | 0.575715 |
| case fatality proportion | 0.462789 |
| patients | 0.534062 |
| ebola virus disease | 0.916381 |
| Emergency Operations Center | 0.464271 |
| Clin Infect Dis. | 0.555619 |
| Ebola outbreaks | 0.542238 |
| clinical presentation | 0.482237 |
| EVD patients | 0.479669 |
| Virus Disease Acquired | 0.476831 |
| Emory University Hospital | 0.454826 |
| West African Ebola | 0.528076 |
|
| convalescent plasma | 0.499005 |
| elevated body temperature | 0.466907 |
| Severe Ebola Virus | 0.584643 |
| Nebraska Medical Center | 0.456036 |
| Ebola virus migrates | 0.576656 |
| United States | 0.555449 |
| ebola virus infection | 0.624917 |
| Sierra Leone | 0.460562 |
| Virus Disease Patients | 0.50462 |
| state health department | 0.461203 |
| current outbreak | 0.487623 |
| Hewlett AL | 0.453259 |
| Zaire Ebola virus | 0.56231 |
| Ebola Case Management | 0.536951 |
| candidate Ebola vaccines | 0.548025 |
| Ebola Virus Exposure | 0.574 |
| Ebola Viral Load | 0.522027 |
| A. Ebola Virus | 0.561271 |
| Ebola treatment units | 0.543328 |
| Virus Infection Complicated | 0.464338 |
| West Africa | 0.615953 |
| Crit Care Med. | 0.500034 |
| et al | 0.455948 |
| Ebola Virus Testing | 0.573378 |
|
CLICK HERE |
| 11585 |
Centers for Disease Control and Prevention |
Html |
en |
NER - Chemical Selection | CDC |
null |
| CDC | 0.839028 |
| biomonitoring | 0.3542 |
| CDC’s National | 0.725553 |
| candidate chemicals | 0.632716 |
| public health evaluations | 0.662347 |
| future editions | 0.646313 |
| Federal Register | 0.981103 |
| National Exposure Reports | 0.683212 |
| assessment | 0.343072 |
| future releases | 0.45963 |
| pages | 0.477734 |
| human chemical exposures | 0.678548 |
| future Reports | 0.576547 |
| categories | 0.36671 |
| chemicals | 0.862994 |
| National Report | 0.751085 |
|
| notice | 0.526315 |
| extensive experience | 0.517508 |
| government agencies | 0.501102 |
| public comment | 0.602716 |
| Human Exposure | 0.793058 |
| draft criteria | 0.487952 |
| Register please visit | 0.497619 |
| environmental chemicals | 0.7958 |
| No. | 0.478309 |
| basis | 0.336274 |
| National Exposure Report | 0.651382 |
| Environmental Health Laboratory | 0.663965 |
| Vol. | 0.478525 |
| possible inclusion | 0.493064 |
| final criteria | 0.495536 |
|
CLICK HERE |
| 11795 |
Centers for Disease Control and Prevention |
Html |
en |
Parents Are The Key to Safe Teen Drivers |
Parents Are the Key to Safe Teen Drivers, a campaign from the Centers for Disease Control and Prevention (CDC), helps parents, pediatricians and communities reduce teen driving injuries and deaths. |
| Centers | 0.433549 |
| CDC | 0.441195 |
| dangers | 0.439454 |
| fact | 0.435696 |
| injuries | 0.433818 |
| important safety features | 0.745804 |
| car crashes | 0.625292 |
| teens | 0.552543 |
| navigation Skip | 0.757681 |
| Prevention | 0.433456 |
| teen driver | 0.867229 |
| ways | 0.434083 |
| Disease Control | 0.590342 |
| road | 0.433118 |
| Community groups | 0.584968 |
| deaths | 0.44095 |
|
| teen driving crashes | 0.857472 |
| list Skip | 0.757445 |
| lives | 0.435521 |
| page options Skip | 0.938103 |
| teen’s safety | 0.727292 |
| pediatricians | 0.521355 |
| teen drivers | 0.692626 |
| risks | 0.435371 |
| Driver inexperience | 0.619638 |
| difference | 0.440149 |
| campaign | 0.433606 |
| main cause | 0.597154 |
| valuable partners | 0.587555 |
| threat | 0.444766 |
| Key | 0.433662 |
| parents | 0.575235 |
|
CLICK HERE |
| 12172 |
Centers for Disease Control and Prevention |
Html |
en |
Meningitis | Lab Manual | Disclosure | CDC |
Introduction to Laboratory Methods for the Diagnosis of Meningitis. |
| reasonable precautions | 0.490389 |
| microbiology staff | 0.481964 |
| country | 0.415234 |
| legal status | 0.490266 |
| free copy | 0.480217 |
| CDC | 0.415257 |
| proprietary products | 0.483357 |
| presentation | 0.415373 |
| formal publication | 0.496469 |
| designations | 0.421447 |
| certain manufacturers | 0.487217 |
| boundaries | 0.416898 |
| warranty | 0.415972 |
| frontiers | 0.417707 |
| area | 0.415206 |
| National Reference Laboratories | 0.548307 |
| delimitation | 0.425465 |
| circumstances | 0.415915 |
| World Health Organization | 0.901305 |
| agreement | 0.415961 |
| maps | 0.415015 |
| preference | 0.419131 |
| authorities | 0.416274 |
| Errors | 0.414337 |
|
| highest integrity | 0.480747 |
| city | 0.415215 |
| damages | 0.416048 |
| document | 0.43254 |
| mention | 0.418055 |
| conjunction | 0.416877 |
| responsibility | 0.414656 |
| rights | 0.417861 |
| public confidence | 0.481711 |
| potential conflict | 0.481167 |
| specific companies | 0.487765 |
| omissions | 0.4202 |
| reviewers | 0.415602 |
| declaration | 0.414473 |
| commercial purposes | 0.490586 |
| declarations | 0.41769 |
| sale | 0.415548 |
| approximate border lines | 0.563206 |
| names | 0.414541 |
| initial capital letters | 0.557741 |
| material | 0.445617 |
| similar nature | 0.487007 |
| contributors | 0.4311 |
| Additional copies | 0.48533 |
|
CLICK HERE |
| 12910 |
Centers for Disease Control and Prevention |
Html |
en |
Preventing Chronic Disease | Demographic and Health Status Differences Among People Aged 45 or Older With and Without Functional Difficulties Related to Increased Confusion or Memory Loss, 2011 Behavioral Risk Factor Surveillance System - CDC |
Preventing Chronic Disease (PCD) is a peer-reviewed electronic journal established by the National Center for Chronic Disease Prevention and Health Promotion. PCD provides an open exchange of information and knowledge among researchers, practitioners, policy makers, and others who strive to improve the health of the public through chronic disease prevention. |
| chronic health condition | 0.563336 |
| mental health | 0.617199 |
| poor physical health | 0.608873 |
| chronic health conditions | 0.562026 |
| functional difficulties | 0.91598 |
| questions | 0.546669 |
| Risk Factor Surveillance | 0.745138 |
| public health implications | 0.560637 |
| BRFSS respondents | 0.577717 |
| Sound Health Care | 0.55826 |
| Disease Control | 0.546419 |
| public health surveillance | 0.630743 |
| complementary log–log regression | 0.544045 |
| community-dwelling respondents | 0.575231 |
| landline respondents | 0.583356 |
| Population Health | 0.555304 |
| Figure. Optional module | 0.546614 |
| ICML | 0.812743 |
| self-reported increased confusion | 0.560265 |
| health behaviors | 0.546748 |
| public health | 0.684409 |
| household activities | 0.546799 |
| cardiovascular disease | 0.547844 |
|
| random-digit–dialed telephone survey | 0.555978 |
| cognitive health issues | 0.562662 |
| health characteristics | 0.549366 |
| poor mental health | 0.608524 |
| social activities | 0.548639 |
| complex sampling design | 0.546132 |
| health surveillance monitors | 0.560918 |
| limited activity | 0.553604 |
| people | 0.545814 |
| BRFSS core survey | 0.584557 |
| respondents | 0.6989 |
| optional module | 0.572675 |
| public health function | 0.565183 |
| public health service | 0.562657 |
| memory loss | 0.642846 |
| cellular telephone respondents | 0.628682 |
| long-term services | 0.548278 |
| health surveillance systems | 0.575046 |
| similarly aged respondents | 0.601129 |
| cognitive impairment | 0.575706 |
| coronary heart disease | 0.544146 |
| confidence intervals | 0.548578 |
| Behavioral Risk Factor | 0.74813 |
|
CLICK HERE |
| 13352 |
Centers for Disease Control and Prevention |
Html |
en |
Notes from the Field: Increase in Reported Adverse HealthEffects Related to Synthetic Cannabinoid Use - United States,January-May 2015 |
Royal Law, MPH1; Josh Schier, MD1; Colleen Martin, MSPH1; Arthur Chang, MD1; Amy Wolkin, DrPH1 (Author affiliations at end of text). |
| moderate effect | 0.549046 |
| stepdown Bonferroni procedure | 0.521032 |
| minor effect | 0.543076 |
| public health messaging | 0.525023 |
| Colleen Martin | 0.481305 |
| Arthur Chang | 0.476825 |
| chi-square test | 0.468951 |
| significant association | 0.529566 |
| initial notification | 0.469576 |
| Law enforcement agencies | 0.535011 |
| telephone calls | 0.530944 |
| substantial residual disability | 0.531418 |
| Environmental Health | 0.472447 |
| median age | 0.471977 |
| retail outlets | 0.473371 |
| plant-derived marijuana | 0.469228 |
| study period | 0.472193 |
| U.S. poison centers | 0.579839 |
| Royal Law | 0.542626 |
| major adverse effect | 0.566065 |
| Monthly calls | 0.530327 |
| plant material | 0.479839 |
| residual disability | 0.579998 |
| various psychoactive chemicals | 0.54501 |
| central reporting centers | 0.518398 |
|
| multiple substances | 0.534108 |
| common means | 0.466382 |
| public health threat | 0.526661 |
| severe medical outcomes | 0.526505 |
| possible adverse health | 0.577319 |
| major effect | 0.485359 |
| synthetic cannabinoid variants | 0.596182 |
| adverse health effects | 0.950697 |
| National Poison Data | 0.695177 |
| period January–May | 0.470664 |
| poison centers | 0.777131 |
| crazy clown | 0.470418 |
| public health | 0.552381 |
| synthetic cannabinoids | 0.717724 |
| synthetic marijuana | 0.5085 |
| Author affiliations | 0.477744 |
| January–May period | 0.470146 |
| Amy Wolkin | 0.478858 |
| severe outcomes | 0.472425 |
| greater public health | 0.527763 |
| severe outcome | 0.565927 |
| calls | 0.620035 |
| herbal products | 0.470491 |
| black mamba | 0.477416 |
|
CLICK HERE |
| 13445 |
Centers for Disease Control and Prevention |
Html |
en |
Launch of a Nationwide Hepatitis C Elimination Program -Georgia, April 2015 |
Please note: An erratum has been published for this article. To view the erratum, please click here. |
| HCV infections | 0.659753 |
| severe liver disease | 0.587242 |
| national HCV seroprevalence | 0.700094 |
| HCV-infected persons | 0.651514 |
| HCV prevalence estimates | 0.735145 |
| health care capacity | 0.556419 |
| HCV diagnostic services | 0.694231 |
| case management support | 0.567665 |
| new HCV medications | 0.672233 |
| health care providers | 0.6068 |
| comprehensive HCV elimination | 0.75149 |
| highest estimated HCV | 0.727665 |
| HCV control activities | 0.692693 |
| liver disease | 0.604236 |
| Elimination Program Treatment | 0.585895 |
| HCV control program | 0.702873 |
| Viral Hepatitis | 0.539756 |
| South Caucasus CDC | 0.565932 |
| universal health care | 0.541465 |
| initial pilot sites | 0.594656 |
| HCV | 0.997354 |
| public health laboratories | 0.54297 |
| Georgia | 0.681428 |
| current HCV prevalence | 0.684985 |
| initial phase | 0.542088 |
|
| HCV continuum | 0.633891 |
| HCV treatment | 0.790212 |
| HCV RNA | 0.639108 |
| HCV infection | 0.714075 |
| Social Affairs | 0.594191 |
| Immunology Research Center | 0.549053 |
| Caucasus CDC Office | 0.565922 |
| curative HCV treatment | 0.735181 |
| Labor Health | 0.547009 |
| health care | 0.726047 |
| public health | 0.567545 |
| HCV epidemiology | 0.658676 |
| Global Health Protection | 0.570598 |
| HCV transmission | 0.657041 |
| free curative treatment | 0.546014 |
| comprehensive HCV prevention | 0.802113 |
| free HCV testing | 0.676715 |
| clinical sites | 0.640144 |
| independent HCV prevalence | 0.682813 |
| Tbilisi | 0.5677 |
| injection drug users | 0.569047 |
| hcv elimination program | 0.929545 |
| Clinical Immunology Research | 0.557453 |
| HCV elimination program. | 0.73203 |
|
CLICK HERE |